GAMMA Investing LLC has recently bought new shares in
Takeda Pharmaceutical Co. in addition to other related investments including
SVB Wealth LLC, Federated Hermes Inc, and Raymond James & Associates increasing their stakes in the company.
ImmunoGen announced a licensing deal to boost Takeda's arsenal, while value investors are contemplating whether Takeda would make a good purchase. There have been bullish indicators with the rating upgrade to a
'Strong Buy' and the company becoming a worthwhile consideration for income generation.
Dividend investors also got good news as the company declared a dividend of
¥94.00. Takeda has experienced a declining trend recently - being down around 6% in about a month - but this has been predicted to offer a buying opportunity for a turnaround. On top of this, Takeda's stock has been deemed
'undervalued', suggesting potential upside. However, in the midst of this, the company's stock hit a new 1-year low, raising some concerns. Takeda faces challenges regarding its rival's ulcerative colitis drug. Despite these concerns, a recent FDA approval announcement provides some tailwinds for the company. Takeda's expanding pipeline underpins its growth but worries persist about overall growth.
Takeda Pharmaceutical Stocks News Analytics from Mon, 09 Jan 2017 08:00:00 GMT to Tue, 07 May 2024 09:08:36 GMT -
Rating 3
- Innovation 1
- Information 7
- Rumor 2
